Boston Scientific

BSX

Market cap $150B

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.

Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?

Boston Scientific rides on strong neuromodulation momentum as sales climb, new technologies gain traction and recent acquisitions expand its pain-treatment reach.

Boston Scientific Corporation ( BSX ) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 8:00 AM EST Company Participants Ken Stein - Senior VP & Global Chief Medical Officer Lauren Tengler - Director of Investor Relations Conference Call Participants Michael Polark - Wolfe Research, LLC Presentation Michael Polark Wolfe Research, LLC Good morning. Welcome, everybody.

The consensus price target hints at a 25.3% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.